TNF-α in asthma

Current Opinion in Pharmacology

Volumn 7, Issue 3, 2007, Pages 279-282

  Berry, Mike ^a   Brightling, Christopher ^b   Pavord, Ian ^b   Wardlaw, AJ ^b  

^a UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^b UNIVERSITY OF LEICESTER   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; CORTICOSTEROID DERIVATIVE; CYTOKINE; ETANERCEPT; INFLIXIMAB; MESSENGER RNA; PLACEBO; RECOMBINANT TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA ANTIBODY;

ANTIINFLAMMATORY ACTIVITY; ASTHMA; CLINICAL TRIAL; DISEASE EXACERBATION; HUMAN; IN VIVO STUDY; LUNG FUNCTION; MORBIDITY; MORTALITY; PRIORITY JOURNAL; QUALITY OF LIFE; RESPIRATORY TRACT DISEASE; REVIEW;

ANTI-ASTHMATIC AGENTS; ANTIBODIES, MONOCLONAL; ASTHMA; CLINICAL TRIALS; HUMANS; IMMUNOGLOBULIN G; RECEPTORS, TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR-ALPHA;

EID: 34248374283     PISSN: 14714892     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.coph.2007.03.001     Document Type: Review

References (32)

1. Medzhitov R., and Janeway Jr. C. Innate immunity. N Engl J Med 343 (2000) 338-344
2. Kriegler M., Perez C., DeFay K., Albert I., and Lu S.D. A novel form of TNF/cachectin is a cell surface cytotoxic transmembrane protein: ramifications for the complex physiology of TNF. Cell 53 (1988) 45-53
3. Zheng Y., Saftig P., Hartmann D., and Blobel C. Evaluation of the contribution of different ADAMs to tumor necrosis factor alpha (TNFalpha) shedding and of the function of the TNFalpha ectodomain in ensuring selective stimulated shedding by the TNFalpha convertase (TACE/ADAM17). J Biol Chem 279 (2004) 42898-42906
4. Smith R.A., and Baglioni C. The active form of tumor necrosis factor is a trimer. J Biol Chem 262 (1987) 6951-6954
5. Brockhaus M., Schoenfeld H.J., Schlaeger E.J., Hunziker W., Lesslauer W., and Loetscher H. Identification of two types of tumor necrosis factor receptors on human cell lines by monoclonal antibodies. Proc Natl Acad Sci USA 87 (1990) 3127-3131
6. Choy E.H., and Panayi G.S. Cytokine pathways and joint inflammation in rheumatoid arthritis. N Engl J Med 344 (2001) 907-916
7. Olsen N.J., and Stein C.M. New drugs for rheumatoid arthritis. N Engl J Med 350 (2004) 2167-2179
8. Ying S., Robinson D.S., Varney V., Meng Q., Tsicopoulos A., Moqbel R., Durham S.R., Kay A.B., and Hamid Q. TNF alpha mRNA expression in allergic inflammation. Clin Exp Allergy 21 (1991) 745-750
9. Bradding P., Roberts J.A., Britten K.M., Montefort S., Djukanovic R., Mueller R., Heusser C.H., Howarth P.H., and Holgate S.T. Interleukin-4, -5, and -6 and tumor necrosis factor-alpha in normal and asthmatic airways: evidence for the human mast cell as a source of these cytokines. Am J Respir Cell Mol Biol 10 (1994) 471-480
10. Thomas P.S., Yates D.H., and Barnes P.J. Tumor necrosis factor-alpha increases airway responsiveness and sputum neutrophilia in normal human subjects. Am J Respir Crit Care Med 152 (1995) 76-80
11. Thomas P.S., and Heywood G. Effects of inhaled tumour necrosis factor alpha in subjects with mild asthma. Thorax 57 (2002) 774-778
12. Adner M., Rose A.C., Zhang Y., Sward K., Benson M., Uddman R., Shankley N.P., and Cardell L.O. An assay to evaluate the long-term effects of inflammatory mediators on murine airway smooth muscle: evidence that TNFalpha up-regulates 5-HT(2A)-mediated contraction. Br J Pharmacol 137 (2002) 971-982
13. Huber M., Beutler B., and Keppler D. Tumor necrosis factor alpha stimulates leukotriene production in vivo. Eur J Immunol 18 (1988) 2085-2088
14. Brightling C.E., Bradding P., Symon F.A., Holgate S.T., Wardlaw A.J., and Pavord I.D. Mast-cell infiltration of airway smooth muscle in asthma. N Engl J Med 346 (2002) 1699-1705
15. van Overveld F.J., Jorens P.G., Rampart M., de Backer W., and Vermeire P.A. Tumour necrosis factor stimulates human skin mast cells to release histamine and tryptase. Clin Exp Allergy 21 (1991) 711-714
16. Coward W.R., Okayama Y., Sagara H., Wilson S.J., Holgate S.T., and Church M.K. NF-kappa B and TNF-alpha: a positive autocrine loop in human lung mast cells?. J Immunol 169 (2002) 5287-5293
17. Lukacs N.W., Strieter R.M., Chensue S.W., Widmer M., and Kunkel S.L. TNF-alpha mediates recruitment of neutrophils and eosinophils during airway inflammation. J Immunol 154 (1995) 5411-5417
18. Slungaard A., Vercellotti G.M., Walker G., Nelson R.D., and Jacob H.S. Tumor necrosis factor alpha/cachectin stimulates eosinophil oxidant production and toxicity towards human endothelium. J Exp Med 171 (1990) 2025-2041
19. Scheurich P., Thoma B., Ucer U., and Pfizenmaier K. Immunoregulatory activity of recombinant human tumor necrosis factor (TNF)-alpha: induction of TNF receptors on human T cells and TNF-alpha-mediated enhancement of T cell responses. J Immunol 138 (1987) 1786-1790
20. Lassalle P., Delneste Y., Gosset P., Tonnel A.B., and Capron A. Potential implication of endothelial cells in bronchial asthma. Int Arch Allergy Appl Immunol 94 (1991) 233-238
21. Walter M.J., Morton J.D., Kajiwara N., Agapov E., and Holtzman M.J. Viral induction of a chronic asthma phenotype and genetic segregation from the acute response. J Clin Invest 110 (2002) 165-175
22. Franchimont D., Martens H., Hagelstein M.T., Louis E., Dewe W., Chrousos G.P., Belaiche J., and Geenen V. Tumor necrosis factor alpha decreases, and interleukin-10 increases, the sensitivity of human monocytes to dexamethasone: potential regulation of the glucocorticoid receptor. J Clin Endocrinol Metab 84 (1999) 2834-2839
23. Amrani Y., Panettieri Jr. R.A., Frossard N., and Bronner C. Activation of the TNF alpha-p55 receptor induces myocyte proliferation and modulates agonist-evoked calcium transients in cultured human tracheal smooth muscle cells. Am J Respir Cell Mol Biol 15 (1996) 55-63
24. Desmouliere A., Geinoz A., Gabbiani F., and Gabbiani G. Transforming growth factor-beta 1 induces alpha-smooth muscle actin expression in granulation tissue myofibroblasts and in quiescent and growing cultured fibroblasts. J Cell Biol 122 (1993) 103-111
25. Sullivan D.E., Ferris M., Pociask D., and Brody A.R. Tumor necrosis factor-alpha induces transforming growth factor-beta1 expression in lung fibroblasts through the extracellular signal-regulated kinase pathway. Am J Respir Cell Mol Biol 32 (2005) 342-349
26. Howarth P.H., Babu K.S., Arshad H.S., Lau L., Buckley M., McConnell W., Beckett P., Al Ali M., Chauhan A., Wilson S.J., et al. Tumour necrosis factor (TNFalpha) as a novel therapeutic target in symptomatic corticosteroid dependent asthma. Thorax 60 (2005) 1012-1018. This was the first description of the use of anti-TNFα in asthma and, although an open study, it generated considerable excitement in the field.
27. Berry M.A., Hargadon B., Shelley M., Parker D., Shaw D.E., Green R.H., Bradding P., Brightling C.E., Wardlaw A.J., and Pavord I.D. Evidence of a role of tumor necrosis factor alpha in refractory asthma. N Engl J Med 354 (2006) 697-708. This was the first double-blind placebo-controlled study of anti-TNFα in asthma. It showed an improvement in lung function and symptoms, and a correlation between the effects of the drug and expression of TNFα on monocytes. Its main weakness was the small number of patients (i.e. 10), making it only a pilot study.
28. Erin E.M., Leaker B.R., Nicholson G.C., Tan A.J., Green L.M., Neighbour H., Zacharasiewicz A.S., Turner J., Barnathan E.S., Kon O.M., Barnes P.J., and Hansel T.T. The effects of a monoclonal antibody directed against tumor necrosis factor-alpha in asthma. Am J Respir Crit Care Med 174 (2006) 753-762
29. Morjaria JB, Chauhan AJ, Bobu KS, Mehta RL, Smith S, North M, Davies DE, Holgate ST: Assessment of a soluble TNFalpha receptor fusion protein (Etanercept) as a novel therapeutic agent for severe refractory asthma. AJRCCM 2006, April Supplement:A16
30. Bongartz T., Sutton A.J., Sweeting M.J., Buchan I., Matteson E.L., and Montori V. Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials. J Am Med Assoc 295 (2006) 2275-2285. This study summarises the experience of anti-TNFα in rheumatoid arthritis from a safety perspective.
31. Rennard SI, Fogarty C, Kelsen S, Long W, Ramsdell J, Allison J, Mahler D, Saadeh C, Siler T, Snell P et al. on behalf of the COPD investigators: The safety and efficacy of infliximab in moderate to severe chronic obstructive pulmonary disease. AJRCCM 2007, in press. This study is the first description of the use of anti-TNF in COPD, and also contains important information on the safety of the approach in airway disease.
32. Aoki T., Hirota T., Tamari M., Ichikawa K., Takeda K., Arinami T., Shibasaki M., and Noquchi E. An association between asthma and TNF-308G/A/polymorphism:meta analysis. J Hum Genet 51 (2006) 677-685